Sanofi, GSK offer 20M COVID-19 vaccine doses to COVAX alliance

By Brian Buntz | October 29, 2020

Sanofi (NSDQ:SNY) and GSK (LON: GSK), which have teamed up to produce a COVID-19 vaccine candidate, have signaled their intent to work with the legal administrator of the COVAX Facility.

The two companies have vowed to produce 200 million doses of a vaccine based on the protein subunit AS03 adjuvant.

Governments, businesses and health organizations have banded together to support the COVAX Facility, which aims to ensure global equitable access to vaccines to treat the novel coronavirus.

Get the full story at our sister site, Drug Discovery & Development.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].